News


VITAL Amyloidosis Study Update

VITAL Amyloidosis Study Update

Per Prothena, following on the heels of completing enrollment in the NEOD001 Phase 2b PRONTO study in March, we are excited to let you know that today they completed enrollment in the Phase 3 VITAL Amyloidosis Study.

With enrollment in this pivotal study now complete (260 patients), Prothena is looking forward to the results which, if positive, will enable them to submit the regulatory package for approval of NEOD001.

More details On NEOD001 here: http://bit.ly/2rLazcz.